
LivaNova PLC LIVN
$ 61.53
-1.2%
Quarterly report 2025-Q3
added 11-05-2025
LivaNova PLC General and Administrative Expenses 2011-2026 | LIVN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses LivaNova PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 526 M | 518 M | 469 M | 472 M | 447 M | 507 M | 462 M | 382 M | 357 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 526 M | 357 M | 460 M |
Quarterly General and Administrative Expenses LivaNova PLC
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 139 M | 138 M | 134 M | - | 127 M | 125 M | 130 M | - | 135 M | 126 M | 124 M | - | 115 M | 116 M | 119 M | - | 109 M | 123 M | 116 M | - | 104 M | 103 M | 228 M | - | 123 M | 127 M | 126 M | - | 115 M | 123 M | 104 M | - | 97.2 M | 94.3 M | 87.3 M | - | 109 M | 121 M | 116 M | - | 41.2 M | 41.2 M | 29.7 M | - | 29.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 228 M | 29.6 M | 112 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
334 M | - | - | $ 17.2 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Alphatec Holdings
ATEC
|
450 M | $ 21.04 | 0.86 % | $ 3.01 B | ||
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Apyx Medical Corporation
APYX
|
22.2 M | $ 3.5 | 1.74 % | $ 121 M | ||
|
Cognyte Software Ltd.
CGNT
|
163 M | $ 9.4 | 1.08 % | $ 675 M | ||
|
Boston Scientific Corporation
BSX
|
5.98 B | $ 95.35 | -0.69 % | $ 140 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
814 M | $ 302.99 | -0.5 % | $ 8.55 B | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Electromed
ELMD
|
39.3 M | $ 29.12 | 1.01 % | $ 246 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Bruker Corporation
BRKR
|
894 M | $ 47.11 | -0.84 % | $ 7.02 K | ||
|
Abbott Laboratories
ABT
|
11.7 B | $ 125.29 | -0.39 % | $ 218 B | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.29 | 2.49 % | $ 123 M | ||
|
InMode Ltd.
INMD
|
8.41 M | $ 14.69 | -1.01 % | $ 1.17 B | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
IRadimed Corporation
IRMD
|
15.9 M | $ 97.28 | -0.5 % | $ 1.23 B | ||
|
LENSAR
LNSR
|
26.5 M | $ 11.63 | - | $ 134 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Myomo
MYO
|
18.4 M | $ 0.91 | -1.58 % | $ 6.42 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Zynex
ZYXI
|
60.4 M | - | - | $ 21.1 M | ||
|
Orthofix Medical
OFIX
|
533 M | $ 15.16 | -1.11 % | $ 578 M | ||
|
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
1.76 B | $ 156.15 | -1.26 % | $ 11.7 B | ||
|
Accuray Incorporated
ARAY
|
47.9 M | $ 0.82 | 2.64 % | $ 84.3 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
12 M | $ 13.68 | 0.81 % | $ 370 M | ||
|
FONAR Corporation
FONR
|
23.5 M | $ 18.56 | -0.22 % | $ 122 M | ||
|
AxoGen
AXGN
|
39 M | $ 32.73 | - | $ 1.45 B | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
Sintx Technologies
SINT
|
4.22 M | $ 3.86 | 2.66 % | $ 14.4 M | ||
|
IRIDEX Corporation
IRIX
|
8.75 M | $ 1.14 | -0.87 % | $ 18.4 M | ||
|
CONMED Corporation
CNMD
|
117 M | $ 40.6 | -1.31 % | $ 1.25 B | ||
|
OrthoPediatrics Corp.
KIDS
|
103 M | $ 17.76 | -1.11 % | $ 410 M |